Lifeboat Foundation

How groups of humans working together collaboratively should redistribute the wealth they create is a problem that has plagued philosophers, economists, and political scientists for years. A new study from DeepMind suggests AI may be able to make better decisions than humans.

AI is proving increasingly adept at solving complex challenges in everything from business to biomedicine, so the idea of using it to help design solutions to social problems is an attractive one. But doing so is tricky, because answering these kinds of questions requires relying on highly subjective ideas like fairness, justice, and responsibility.

For an AI solution to work it needs to align with the values of the society it is dealing with, but the diversity of political ideologies that exists today suggests that these are far from uniform. That makes it hard to work out what should be optimized for and introduces the danger of the developers’ values biasing the outcome of the process.

A listeria outbreak blamed for the death of one person and the hospitalization of 22 people across 10 states has been linked to ice cream made in Florida, the federal authorities said on Saturday.

Big Olaf Creamery, a family-owned company in Sarasota, Fla., exclusively sells ice cream in Florida, the federal Centers for Disease Control and Prevention said. Of those hospitalized, 10 people lived out of state and had visited Florida in the previous month, the C.D.C. said.

The infections tied to Big Olaf ice cream products occurred over the last six months and affected people less than a year old to 92 years old, the C.D.C. said. Five became ill during pregnancy, with one experiencing a fetal loss.

Hear from Nobel laureate Jennifer Doudna on the four ways that CRISPR gene editing technologies will revolutionize healthcare.

In her 31 March talk at the Frontiers Forum, Prof Jennifer Doudna outlined how CRISPR-based therapies are already transforming the lives of patients with previously limited treatment options. She also gave her vision for how her serendipitous discovery will revolutionize healthcare for us all. The session was attended by over 9,200 representatives from science, policy and business across the world.

Continue reading “Jennifer Doudna | Four ways that CRISPR will revolutionize healthcare” »

A recent study indicates the prevalence of brain changes from limbic-predominant age-related TDP-43 encephalopathy might be approximately 40% in older adults and as high as 50% in people with Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

PHILADELPHIA — In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The treatment would eradicate their end-stage leukemia, generate headlines across the globe, and usher in a new era of highly personalized medicine. Called Chimeric Antigen Receptor (CAR) T cells, these genetically modified tumor-targeting cells are a living drug made for each patient out of their own cells. Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.

“This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this “living drug” that works effectively against cancer cells,” said first author J. Joseph Melenhorst, PhD, a research professor of Pathology and Laboratory Medicine at Penn. “Witnessing our patients respond well to this innovative cellular therapy makes all of our efforts so worthwhile. being able to give them more time to live and to spend it with loved ones.”

CLL, the first cancer in which CAR T cells were studied and used at Penn, is the most common type of leukemia in adults. While treatment of the disease has improved, it remains incurable with standard approaches. Eventually, patients can become resistant to most therapies, and many still die of their disease.

A network of 1,600 video cameras surveils Marseille residents in the name of public safety, but this type of policing tool is rarely useful in solving crimes. Digital rights activists are fighting back.

For Nano the creep of increased surveillance has personal resonance. She grew up in Albania as it lurched between different political regimes in the 1990s. Her father, a politician, opposed the party that was in power for part of that time. “It was a very difficult period for us, because we were all being watched,” she says. Her family suspected that the authorities had installed bugs in the walls of their home. But even in France, freedoms are fragile. “These past five years France has lived for much of the time in a state of emergency,” she says. “I’ve seen more and more constraints put on our liberty.”

Concerns have been raised throughout the country. But the surveillance rollout has met special resistance in Marseille, France’s second-biggest city. The boisterous, rebellious Mediterranean town sits on some of the fault lines that run through modern France. Known for hip bars, artist studios, and startup hubs, it is also notorious for drugs, poverty, and criminal activity. It has one of the most ethnically diverse populations in Europe but is stranded in Provence-Alpes-Côte d’Azur, a region that leans far right. The city pushes back. Its attitude could be summed up by graffiti you might pass as you drive in on the A7 motorway: “La vie est (re)belle.”

Continue reading “Marseille’s battle against the surveillance state” »

Earlier I posted results. Those posts did not include info here concerning topical E5 human trials to start in a month or so and if the results are good they will start up a U.S. factory. So far, 3 treated rats have a 13% longer lifespan than the max for a lab rat and 3 of them are still alive.

In this video we report on the June 2022 update from Dr. Katcher’s experiment with E5, where he is testing to see how long the rats will stay alive if they are given an E5 injection every 90 days. The experiment appears to be coming to an end with only 3 treated rats still alive. But a new experiment has started as well as a human trial of E5 used topically being planned.

Continue reading “Dr Katcher’s E5 Experiment June 2022 Update | Review” »

Jun Huang from the Pritzker School of Molecular Engineering at the University of Chicago.

Founded in 1,890, the University of Chicago (UChicago, U of C, or Chicago) is a private research university in Chicago, Illinois. Located on a 217-acre campus in Chicago’s Hyde Park neighborhood, near Lake Michigan, the school holds top-ten positions in various national and international rankings. UChicago is also well known for its professional schools: Pritzker School of Medicine, Booth School of Business, Law School, School of Social Service Administration, Harris School of Public Policy Studies, Divinity School and the Graham School of Continuing Liberal and Professional Studies, and Pritzker School of Molecular Engineering.

Irvine, Calif., June 30, 2022 — University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, a common form of hair loss in both women and men.

The study, published online today in Developmental Cell, determined the precise mechanism by which the dermal papilla cells – specialized signal-making fibroblasts at the bottom of each hair follicle – promote new growth. Although it’s well known that dermal papilla cells play a pivotal role in controlling hair growth, the genetic basis of the activating molecules involved has been poorly understood.

“At different times during the hair follicle life cycle, the very same dermal papilla cells can send signals that either keep follicles dormant or trigger new hair growth,” said Maksim Plikus, Ph.D., UCI professor of developmental & cell biology and the study’s corresponding author. “We revealed that the SCUBE3 signaling molecule, which dermal papilla cells produce naturally, is the messenger used to ‘tell’ the neighboring hair stem cells to start dividing, which heralds the onset of new hair growth.”